A U.S. judge overturned a $140.1 million verdict against AbbVie Inc. in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.

Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.

U.S. FDA staff flagged concerns about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp.

Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.

La Jolla Pharmaceutical said the U.S. Food and Drug Administration approved its drug Giapreza to treat dangerously low blood pressure.

Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers.

The U.S. Food and Drug Administration approved Roche’s first-in-class therapy Hemlibra for hemophilia suffers.

Portola Pharmaceuticals announced that the U.S. Food and Drug Administration approved the potential blockbuster drug Bevyxxa (betrixaban).

Roche Holding AG’s emicizumab drug for treating hemophilia A showed it worked in a phase III study, the Swiss drugmaker said.

U.S. government scientists have raised questions about the potential risks to patients of heart attacks and blood clots from Abbott Laboratories’ novel coronary stent that dissolves after it is implanted. Abbott is seeking U.S. approval to sell the stent, called Absorb, as an alternative to metal stents currently used to prop open arteries cleared of […]